Story thread · 4 reports / 3 sources
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
investors.com · 13m
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. The post Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares appeared first on Investor's Business Daily .
First report: Axoltis says its Phase 2 study for an experimental ALS drug failed — endpts.com, 1d
The coverage
- Novartis scraps ALS therapy after mid-stage trial setback
seekingalpha.com · 1h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.